Novartis’ Leqvio cuts LDL levels by 50% over three years: #ESC23

No­var­tis said that 78.4% of pa­tients in a Phase III met a pre-spec­i­fied low-den­si­ty lipopro­tein cho­les­terol tar­get af­ter tak­ing the siR­NA cho­les­terol drug Leqvio for three years, with pa­tients re­port­ing a 49.4% de­crease, on av­er­age, in their LDL lev­els over the same pe­ri­od of time.

The Swiss drug­mak­er un­veiled the da­ta Mon­day at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy meet­ing in Am­s­ter­dam. ORI­ON-8 is a com­bi­na­tion, open-la­bel ex­pan­sion study that re­cruit­ed 3,274 pa­tients from four pre­vi­ous tri­als as part of the com­pa­ny’s Leqvio clin­i­cal re­search pro­gram, called Vic­tO­RI­ON.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.